<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202017000300284</article-id>
<article-id pub-id-type="doi">10.29277/ruc/32.3.9</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Lo mejor del Congreso de la Sociedad Europea de Cardiología 2017]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bonino]]></surname>
<given-names><![CDATA[Agustina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cristar]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Revista Uruguaya de Cardiología  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>32</volume>
<numero>3</numero>
<fpage>284</fpage>
<lpage>290</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202017000300284&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202017000300284&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202017000300284&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: A pesar de la tragedia que el último atentado terrorista provocó en las ramblas de Barcelona, la comunidad cardiológica catalana tuvo que reponerse rápidamente para ser anfitriona del mayor evento cardiovascular de Europa: el ESC CONGRESS 2017. Del 26 al 30 de agosto, en decenas de mesas redondas, más de 31.000 cardiólogos de todo el mundo se reunieron para actualizar sus conocimientos e intercambiar novedades en ciencia, innovación e investigación en cardiología en más de 500 sesiones y más de 4.500 presentaciones de abstracts (1). Se presentaron nuevas guías para el manejo del infarto agudo de miocardio, enfermedad valvular, enfermedad arterial periférica y recomendaciones para el uso de terapia antiplaquetaria dual. Se celebraron los 40 años de la intervención coronaria percutánea (PCI), realizada por Andreas Grüntzig por primera vez el 16 de setiembre de 1977(1). Realizaremos un breve resumen de algunos de los principales trabajos científicos presentados durante este evento que sin duda tendrán un impacto en nuestra práctica clínica diaria. - Canakinumab Anti-Inflammatory Thrombosis Outcome Study: CANTOS. - Global Anticoagulant Registry in the Field-Atrial Fibrillation (Registro Global de Anticoagulantes en el Campo de la Fibrilación Auricular): GARFIELD-AF. - Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation: CASTLE-AF. - Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary Results]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary: Despite the last terrorist attack tragedy at La Rambla in Barcelona, Catalonian cardiologic community had to quickly recover from the episode to host the major European cardiovascular event: the ESC CONGRESS 2017. From august 26th to 30th, more than 31.000 cardiologists from all over the world met to update their knowledge and share the state of the art science, innovation and cardiologic investigation in more than 500 sessions and more than 4.500 abstracts presentations. New guidelines for the management of acute ST-segment elevation myocardial infarction, valvular heart disease, peripheral vascular disease and recommendations on dual antiplatelet therapy were presented. Fourty years of percutaneous coronary intervention (PCI), performed for the first time by Andreas Grüntzig on September 16th, 1977, was celebrated. We will expose a brief summary of some of the main scientific works presented at the congress which will undoubtedly have an impact on our daily clinical practice. - Canakinumab Anti-Inflammatory Thrombosis Outcome Study: CANTOS. - Global Anticoagulant Registry in the Field-Atrial Fibrillation: GARFIELD-AF. - Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation: CASTLE-AF. - Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary Results]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Congresos]]></kwd>
<kwd lng="es"><![CDATA[Cardiología]]></kwd>
<kwd lng="es"><![CDATA[Cantos]]></kwd>
<kwd lng="es"><![CDATA[Garfield-Af]]></kwd>
<kwd lng="es"><![CDATA[Castle-Af]]></kwd>
<kwd lng="es"><![CDATA[Compass]]></kwd>
<kwd lng="en"><![CDATA[Congress]]></kwd>
<kwd lng="en"><![CDATA[Cardiology]]></kwd>
<kwd lng="en"><![CDATA[Cantos]]></kwd>
<kwd lng="en"><![CDATA[Garfield-Af]]></kwd>
<kwd lng="en"><![CDATA[Castle-Af]]></kwd>
<kwd lng="en"><![CDATA[Compass]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>European Society of Cardiology</collab>
<source><![CDATA[About ESC Congress]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridker]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Everett]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Thuren]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[MacFadyen]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Ballantyne]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1119-31</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridker]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[MacFadyen]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Thuren]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Everett]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Glynn]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomized, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>390</volume>
<numero>10105</numero>
<issue>10105</issue>
<page-range>1833-42</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="confpro">
<collab>European Society of Cardiology</collab>
<source><![CDATA[ESC Congress]]></source>
<year>2017</year>
<conf-name><![CDATA[ CANTOS: anti-infammatory drug cuts CV events, cancer. Presentation]]></conf-name>
<conf-date>24 - 30 August, 2017</conf-date>
<conf-loc>Barcelona </conf-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wendling]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Coverage from the European Society of Cardiology (ESC) Congress 2017- Conference: CANTOS,anti-inflammatory drug cuts CV events, cancer]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Medscape ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrington]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting Inflammation in Coronary Artery Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1197-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Thrombosis Research Institute</collab>
<source><![CDATA[Global Anticoagulant Registry in the Field.Real-world insights from GARFIELD-AF Registry presented at ESC Congress 2017]]></source>
<year>2017</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[TRI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>European Society of Cardiology</collab>
<source><![CDATA[ESC final congress presentations: symposium presentations]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kakkar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[ESC Congress 2017]]></source>
<year>2017</year>
<conf-name><![CDATA[ Atrial fibrillation - A bystander or cause of morbidity and mortality: insights from the GARFIELD-AF registry.]]></conf-name>
<conf-date>24 - 30 August, 2017</conf-date>
<conf-loc>Barcelona </conf-loc>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeffrey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[CASTLE-AF: ablation reduces mortality in LV dysfunction, AF.]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Medscape ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Estudio CASTLE-AF: Ablación por catéter comparada con la terapia convencional en pacientes con fibrilación auricular y disfunción ventricular izquierda]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[SAC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>American College of Cardiology</collab>
<source><![CDATA[CASTLE-AF: catheter ablation vs. conventional therapy for patients with AFib and LV dysfunction. Washington,]]></source>
<year>2017</year>
<publisher-loc><![CDATA[DC ]]></publisher-loc>
<publisher-name><![CDATA[ACC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dagenais]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Shestakovska]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[COMPASS Investigators]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1319-30</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>European Society of Cardiology</collab>
<source><![CDATA[Rivaroxaban plus aspirin improves outcomes in stable cardiovascular disease (COMPASS)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
